Septerna (SEPN) Stock Overview

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. More details

SEPN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 36.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market

SEPN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW470,695 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

470,695 investors already sharing narratives

View all narratives

Septerna, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Septerna
Historical stock prices
Current Share Price	US$45.14
52 Week High	US$51.10
52 Week Low	US$10.74
Beta	0
1 Month Change	32.49%
3 Month Change	67.50%
1 Year Change	285.15%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	110.93%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	SEPN	US Pharmaceuticals	US Market
7D	16.3%	2.5%	1.0%
1Y	285.2%	55.5%	18.4%

Return vs Industry: SEPN exceeded the US Pharmaceuticals industry which returned 55.5% over the past year.

Return vs Market: SEPN exceeded the US Market which returned 18.4% over the past year.

Price Volatility

Is SEPN's price volatile compared to industry and market?
SEPN volatility
SEPN Average Weekly Movement	11.1%
Pharmaceuticals Industry Average Movement	9.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SEPN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SEPN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2019	123	Jeff Finer	septerna.com

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.

Septerna, Inc. Fundamentals Summary

How do Septerna's earnings and revenue compare to its market cap?
SEPN fundamental statistics
Market cap	US$2.11b
Earnings (TTM)	-US$24.24m
Revenue (TTM)	US$98.88m

21.3x

P/S Ratio

-86.9x

P/E Ratio

Is SEPN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SEPN income statement (TTM)
Revenue	US$98.88m
Cost of Revenue	US$0
Gross Profit	US$98.88m
Other Expenses	US$123.12m
Earnings	-US$24.24m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.52
Gross Margin	100.00%
Net Profit Margin	-24.51%
Debt/Equity Ratio	0%

How did SEPN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/14 03:16
End of Day Share Price	2026/08/13 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Septerna, Inc. is covered by 10 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joshua Schimmer	Cantor Fitzgerald & Co.
Seamus Fernandez	Guggenheim Securities, LLC
Raghuram Selvaraju	H.C. Wainwright & Co.